S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, positive-drug parallel controlled, multicenter phase III trial of
the efficacy and safety of S086 tablets in patients with chronic heart failure with reduced
ejection fraction (HFrEF)